- Cresco Labs posted Q4 2023 revenue of $188.2 million with GAAP gross margin approximately 47.0% (adjusted discussions cite a 53% gross margin in commentary), and adjusted EBITDA of $55.0 million (margin ≈ 29%), signaling meaningful margin expansion despite ongoing price compression in core markets. Net income was modest at $2.6 million, with diluted EPS of $0.008 for the quarter. Management framed these results as a culmination of the Year of the Core strategy—focusing on core markets, improving operating efficiency, and strengthening cash flow. For the full year 2023, Cresco highlighted a significant improvement in margins and a substantial step-up in operating cash flow, culminating in positive free cash flow, supported by capably executed cost reductions and productivity gains.
- Management signaled a disciplined 2024 plan built around continued gross margin resilience in the mid-50% range (target around 50% gross margin), ongoing SG&A discipline, and a capital expenditure program aimed at accelerating adult-use catalysts in Ohio, Pennsylvania, and Florida. The company expects Q1 2024 revenue to be down in the low-single digits due to pricing pressure, with Q2–Q3 roughly flat and a rebound in Q4 driven by Ohio adult-use conversions. Management asserts 2024 could be a record year for operating and free cash flow, assuming continued efficiency gains offsetting price compression.
- Cresco’s near-term growth catalysts include AU conversions in Ohio, Pennsylvania, and Florida, robust branded wholesale leadership (House of Brands), and a scalable Sunnyside e-commerce and loyalty platform. The company also emphasized its leadership in key markets (Illinois, Pennsylvania, Massachusetts) and ongoing in-house genetics program intended to reach a majority of products on wholesale menus as Cresco genetics exclusive offerings by 2025. While structural leverage remains elevated, the firm’s balance sheet shows meaningful cash on hand, with net debt and capitalization metrics signaling leverage that remains a consideration for forward-looking risk as it funds CapEx and AU investments.